US2017029778A1PendingUtilityA1
Sc-beta cells and compositions and methods for generating the same
Est. expiryJun 11, 2033(~6.9 yrs left)· nominal 20-yr term from priority
Inventors:Quinn P. PetersonFelicia J. PagliucaDouglas A. MeltonJeffrey R. MillmanMichael Saris SegelMads GurtlerAlireza RezaniaBenjamin Fryer
A61P 5/48A61P 5/50C12N 2501/41C12N 2501/999C12N 2501/117C12N 2501/395C12N 2501/11C12N 5/0696C12N 2501/998C12N 2506/45C12N 5/0676A61K 35/39C12N 2501/40C12N 2506/03C12N 2501/15C12N 5/0606C12N 2506/22C12N 2501/16C12N 2501/385C12N 2506/02C12N 2501/727C12N 2501/375C12N 5/0678A61P 3/10C12N 2500/38
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 - 339 . (canceled)
340 . A culture medium comprising a) Alk5 inhibitor, b) triiodothyronine (T3), optionally c) staurosporine, and optionally d) CMRLS.
341 . A culture medium comprising a) KGF, b) SANT1), and optionally c) RA, wherein the culture medium is substantially free of PdbU and LDN193189.
342 . Use of the culture medium of claim 2 to induce the in vitro differentiation of Pdx1-positive pancreatic progenitor cells into NKX6-1-positive pancreatic progenitor cells.
343 . A culture medium comprising a) TGF-β signaling pathway inhibitor, b) a TH pathway activator, and at least one additional β cell-maturation factor selected from the group consisting of i) XXI, ii) Betacellulin, iii) a low concentration of a RA signaling pathway activator, and iv) a SHH pathway inhibitor.Join the waitlist — get patent alerts
Track US2017029778A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.